NCT02306187

The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis

The Effectiveness of Eldecalcitol in the Osteoporotic Patients Who Are Bisphosphonate Non-responders After Long-term Bisphosphonate Treatment

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Shinshu University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

In the patients with osteoporosis, bisphosphonates (BPs) are a golden standard treatment. However, the bone turnover markers or the bone mineral density (BMD) are not improved in some osteoporotic patients even though they have taken BPs and alfacalcidol more than several years. In those case, the investigators better off prescribing BPs and Eldecalcitol, instead of BPs and Alfacalcitol.

Detailed description

Alfacalcitol and Eldecalcitol are the similar vitamin D drugs. However, Eldecalcitol is an improved vitamin D drug than Alfacalcitol. Therefore, we investigate the effectiveness of Eldecalcitol in this study.

Conditions

• Osteoporosis

Interventions

Type	Name	Description
DRUG	Edirol	Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.

Timeline

• Start date: 2014-12-01
• Primary completion: 2022-12-01
• Completion: 2024-12-01
• First posted: 2014-12-03
• Last updated: 2021-09-21

Locations

1 site across 1 country: Japan